Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089219 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00089219 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 39 participants.
The verdict
NCT00089219, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating patients with stage IIIB, stage IIIC, or stage IV melanoma.
Interventions
- BIOLOGICAL GM-CSF
- BIOLOGICAL 6MHP
- BIOLOGICAL IFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089219
The ClinicalTrials.gov registry entry for NCT00089219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GM-CSF is the first listed.
NCT00089219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089219 about?
NCT00089219 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying three different doses of a vaccine and comparing them to see how well they work in treating patients with stage IIIB, stage IIIC, or stage IV melanoma.
What is the current status of trial NCT00089219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00089219?
The interventions under investigation include: GM-CSF (BIOLOGICAL), 6MHP (BIOLOGICAL), IFA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089219?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.